相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1982
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A real-world evidence study published in Biology of Sex Differences found that romosozumab significantly outperformed PTH (1-34) analogs in reducing osteoporotic fractures in women. - The anti-sclerostin monoclonal antibody offers a dual mechanism of action, both inhibiting bone resorption and stimulating new bone formation, providing advantages over traditional therapies. - High-risk populations, particularly women with previous fractures or significant bone loss, showed substantial benefits from romosozumab treatment with manageable safety profiles. - A separate study demonstrated that adding romosozumab to ongoing denosumab therapy improved lumbar spine bone mineral density significantly within 6 months in postmenopausal women with severe osteoporosis.
- EdiVite, a University of Verona spinoff, initiated Europe's first field trial of gene-edited Chardonnay vines to enhance resistance against downy mildew, a significant fungal disease. - The CRISPR-Cas9 technology was used to inactivate a gene (_DMR6_ family) that suppresses the plant's immune defense, potentially reducing the need for fungicides in viticulture. - Other Italian research groups, including the Edmund Mach Foundation and CREA-VE, are developing gene-edited vines with enhanced protection against fungal diseases like powdery mildew. - Italy's shift towards embracing New Genomic Techniques (NGTs) is highlighted by government support and the experimental release of gene-edited rice, despite past opposition to GMOs.
